The ability to analyze multiple genes at the same time has led to the estimate that 20% to 25% of women with ovarian cancer have an inherited mutation in a cancer‑predisposing gene. Although this association has been noted for a while, until recently there was not enough data available to determine the lifetime ovarian cancer risk for women with a mutation in some of these genes.
Multiplex genetic testing in BRCA1/2-negative cancer patients with in-person genetic counseling allows informed decision-making while decreasing short-term anxiety, according to data presented at the 2015 San Antonio Breast Cancer Symposium.
Prostate cancer is the most common nondermatologic cancer in males in the United States.1 Incidence and mortality rates vary significantly between countries. In the United States, the lifetime risk of developing prostate cancer is approximately 1 in 7, with an incidence similar to that of breast cancer.
The association of POLE and POLD1 with colorectal cancer risk was demonstrated in 2013. Palles and colleagues studied families with a dominant pattern of inherited colorectal cancer and multiple adenomas through whole genome sequencing.
The number of genes associated with breast cancer risk continues to increase. Recently, through whole exome sequencing, 2 groups of researchers have demonstrated that mutations in RECQL increase the risk of breast cancer.
The Oncology Nurse–APN/PA conducted an interview with Jennifer Temel, MD. The written interview is based on a presentation at the 2015 Annual Meeting of the American Society of Clinical Oncology, Phase III Trials for Anamorelin in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia (ROMANA 1 and 2).
New Data Suggest Clinicians Should Consider Genetic Counseling and BRCA1/2 Testing for Any Patient with Pancreatic Adenocarcinoma
Pancreatic cancer represents 3% of new cancer cases each year, with the average age of diagnosis being 71 years.
Due to the high mortality rate and lack of effective surveillance methods, identifying women at increased risk for ovarian cancer is crucial for offering risk-reducing procedures.
The first multigene panels for colorectal cancer became clinically available in 2012. Prior to that date, clinical testing for inherited colorectal cancer syndromes typically proceeded in a sequential fashion. A clinician would develop a differential diagnosis and test corresponding genes in order of those most likely to have a causative mutation. Thus, analyzing multiple genes for inherited colorectal cancer risk was both time intensive and costly.
ou may have heard about this gene on the radio or in a news article lately. What’s all the fuss about? On August 7, 2014, the New England Journal of Medicine (NEJM) published an article discussing breast cancer risk in families with mutations in PALB2.
Page 2 of 4
Results 11 - 20 of 40
Results 11 - 20 of 40